Injectable Biologics: What Is the Evidence?

Eva Kubrova, Ryan S. D'Souza, Christine L. Hunt, Qian Wang, Andre J. Van Wijnen, Wenchun Qu

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Injectable biologics have attracted considerable interest in the field of musculoskeletal medicine. Biologics encompass a broad and diverse group of human tissue-derived therapeutics. The most commonly reported biologics for use in musculoskeletal conditions include platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stem cells, microfragmented fat, stromal vascular fraction, amniotic membrane-based products, and autologous conditioned serum. The benefits of biologics in tissue healing and regeneration are thought to be derived from their trophic, paracrine, and immunomodulatory functions. The purpose of this review is to define commonly used injectable biologics and to appraise current evidence on its efficacy in the treatment of musculoskeletal disease.

Original languageEnglish (US)
Pages (from-to)950-960
Number of pages11
JournalAmerican Journal of Physical Medicine and Rehabilitation
Issue number10
StatePublished - Oct 1 2020


  • Biological Products
  • Injectable
  • Mesenchymal Stem Cells
  • Osteoarthritis
  • Platelet-Rich Plasma
  • Tendinopathy

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation


Dive into the research topics of 'Injectable Biologics: What Is the Evidence?'. Together they form a unique fingerprint.

Cite this